|[May 06, 2014]
Derma Sciences to Present at Sidoti Semiannual Micro-Cap Conference on May 9
PRINCETON, N.J. --(Business Wire)--
Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration
company focused on advanced wound care, announced today that Edward J.
Quilty, the Company's chairman and chief executive officer, will present
a corporate overview and update at the Sidoti & Company Semiannual
Micro-Cap Conference on Friday, May 9, 2014 at 10:40 a.m. Eastern time.
The conference is being held at the Grand Hyatt New York Hotel in New
Management will be available for one-on-one meetings at the conference.
Please contact conference organizers to schedule a meeting.
About Derma Sciences, Inc.
Derma Sciences is a tissue regeneration company focused on advanced
wound and burn care. It offers a line of products with patented
technologies to help better manage chronic and hard-to-heal wounds, many
of wich result from diabetes and poor vascular functioning. The company
recently entered the $500 million market for skin substitute products
with its licensing of AMNIOEXCEL® and AMNIOMATRIX® in the first quarter
of 2014. AMNIOEXCEL was launched to customers in March 2014 and
AMNIOMATRIX will be launched in the second quarter. Its MEDIHONEY®
product is the leading brand of honey-based dressings for the management
of wounds and burns. The product has been shown in clinical studies to
be effective in a variety of indications. TCC-EZ® is its gold-standard
total contact casting system for diabetic foot ulcers. Other novel
products introduced into the $14 billion global wound care market
include XTRASORB® for better management of wound exudate, and BIOGUARD®
for barrier protection against microbes and other contaminants. Its
pharmaceutical wound care products include DSC127, which is currently in
Phase 3 clinical trials for the healing of diabetic foot ulcers. The
drug candidate is also part of a BARDA grant program for the
healing/prevention of tissue damage due to ionizing radiation exposure.
The patented API peptide used in DSC127 is also in preclinical testing
for scar prevention/reduction. The company also offers a full product
line of traditional dressings.
For more information please visit www.dermasciences.com.
[ Back To Technology News's Homepage ]